Pfizer Inc. (PFE) Competitors & Peers
The 5 largest companies in the same industry as Pfizer Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Competitor | $1,152.44 | P/E 38.2RSI 47Cap 1.03 T |
| JNJ | Peer | $270.22 | P/E 31.0RSI 56Cap 651.2 B |
| ABBV | Peer | $264.02 | P/E 74.2RSI 59Cap 466.6 B |
| MRK | Competitor | $147.15 | P/E 115.9RSI 58Cap 363.0 B |
| AZN | Peer | $166.14 | P/E 24.5RSI 51Cap 253.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- CDXSSupplier
Own 10-Q customer-concentration disclosure: Pfizer = 12% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - PSNLSupplier
Own 10-Q customer-concentration disclosure: PfizerInc = 11% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CLDXSupplier
Own 10-K customer-concentration disclosure: PfizerInc = 85% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - NKTRSupplier
Own 10-K customer-concentration disclosure: Pfizer = 12% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - OPKSupplier
Own 10-K customer-concentration disclosure: Pfizer = 13% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MRVISupplier
Own 10-K customer-concentration disclosure: PfizerInc = 26% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - HALOSupplier
Own 10-K customer-concentration disclosure: Pfizer = 1% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - RGENSupplier
Own 10-Q customer-concentration disclosure: Pfizer = 11% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - FCELSupplier
Own 10-K customer-concentration disclosure: PfizerInc. = 2% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - BDSXSupplier
Own 10-Q customer-concentration disclosure: PfizerInc = 16% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - EYPTSupplier
Own 10-K customer-concentration disclosure: PfizerInc = 74% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
McKesson is one of Pfizer's primary pharmaceutical wholesale distributors in the US, distributing the majority of Pfizer's branded and biosimilar products.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- SEAGENPartner
Pfizer acquired Seagen in December 2023 for approximately $43 billion, gaining its ADC (antibody-drug conjugate) oncology portfolio including Padcev, Adcetris, Tukysa, and Tivdak.
Model-inferred, unverified — treat as a lead, not evidence - BNTXPartner
Pfizer-BioNTech Comirnaty COVID-19 vaccine partnership.
Model-inferred, unverified — treat as a lead, not evidence - SEAGENMerger
Pfizer acquired Seagen in December 2023 for approximately $43 billion, gaining its ADC (antibody-drug conjugate) oncology portfolio including Padcev, Adcetris, Tukysa, and Tivdak.
Model-inferred, unverified — treat as a lead, not evidence - BMYPartner
Pfizer and BMS co-develop and co-commercialize Eliquis (apixaban) globally — one of the most valuable pharmaceutical co-promotion arrangements in history.
Model-inferred, unverified — treat as a lead, not evidence - MRKCompetitor
Top pharma majors.
Model-inferred, unverified — treat as a lead, not evidence - ERASPartner
Erasca partners with Pfizer on combination trials for naporafenib.
Model-inferred, unverified — treat as a lead, not evidence - HALOPartner
Pfizer licenses ENHANZE technology for subcutaneous formulations.
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
Eli Lilly and Pfizer compete in oncology (Ibrance vs Verzenio CDK4/6 inhibitors) and internal medicine/immunology.
Model-inferred, unverified — treat as a lead, not evidence - HLNPartner
Pfizer contributed its consumer health business to form Haleon and maintains a significant equity stake.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora distributes Pfizer products globally.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal distributes Pfizer products to US healthcare.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson is among Pfizer's largest US pharma distributors.
Model-inferred, unverified — treat as a lead, not evidence - PCVXCompetitor
Vaxcyte VAX-31 vs Pfizer Prevnar 20 pneumococcal competition.
Model-inferred, unverified — treat as a lead, not evidence - HIMSSupplier
Hims & Hers relies on major generic manufacturers like Pfizer (Upjohn/Viatris spinoff) for generic versions of Viagra (Sildenafil).
Model-inferred, unverified — treat as a lead, not evidence - AVTRCustomer
Pfizer purchases high-purity bioprocess reagents and single-use fluid handling bags for drug manufacturing.
Model-inferred, unverified — treat as a lead, not evidence - WBASupplier
Walgreens dispenses Pfizer Rx.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal Health is one of Pfizer's three primary wholesale distributors.
Model-inferred, unverified — treat as a lead, not evidence - CELCCompetitor
Celcuity's gedatolisib competes with Pfizer's pipeline therapies.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora is one of Pfizer's three primary wholesale distributors, providing pharmaceutical distribution across specialty and primary care channels.
Model-inferred, unverified — treat as a lead, not evidence - IEXCustomer
IDEX supplies precision fluidic valves for Pfizer manufacturing plants.
Model-inferred, unverified — treat as a lead, not evidence - TECHCustomer
Pfizer purchases research-grade proteins and assays for drug discovery.
Model-inferred, unverified — treat as a lead, not evidence - CVSSupplier
CVS dispenses Pfizer prescriptions.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Pfizer is a top-20 pharma Veeva Vault customer.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Pfizer uses Veeva Vault Clinical / Quality / Regulatory.
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
Pfizer discontinued danuglipron (oral GLP-1); competition vs Lilly orforglipron.
Model-inferred, unverified — treat as a lead, not evidence - CTEVCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRDFCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CSTLCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - MRKPartner
Pfizer and Merck co-promote Eliquis (apixaban) globally — Pfizer developed it, Bristol-Myers Squibb and Pfizer co-own it, and Merck co-promotes in certain markets.
Model-inferred, unverified — treat as a lead, not evidence - CSCIFCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CSBRCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRVSCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRVOCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CSLLYCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRVWCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRMDCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRONCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence - CRDLCompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence